TY - JOUR
T1 - Effects of Pioglitazone On Lipoprotein(a)
T2 - A Meta-analysis
AU - Jamialahmadi, Tannaz
AU - Mirhadi, Elaheh
AU - Reiner, Željko
AU - Abass, Kasim Sakran
AU - Almahmeed, Wael
AU - S. Virani, Salim
AU - Sahebkar, Amirhossein
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Purpose of Review: To evaluate the effect of pioglitazone, a member of the thiazolidinedione family of drugs known for its antihyperglycemic properties, on lipoprotein (a) [Lp(a)]. Pioglitazone is recognized for enhancing insulin sensitivity and β-cell function, and it also has a positive influence on the overall lipid profile. Recent Findings: Meta-analysis of 7 studies (4 RCTs and three non-RCTs) including 254 patients showed a significant decrease of circulating Lp(a) levels after treatment with pioglitazone (SMD: -0.373, 95% CI: -0.642, -0.104, p = 0.007). The reduction in circulating Lp(a) was robust in the leave-one-out sensitivity analysis. The presented results were obtained following a comprehensive literature search conducted in PubMed, Scopus, Embase, and Web of Science, covering studies from their inception up to March 1, 2025. Summary: Pioglitazone significantly decreases circulating Lp(a) concentrations. This decrease might have a beneficial effect on atherosclerotic cardiovascular disease (ASCVD) in high-risk patients.
AB - Purpose of Review: To evaluate the effect of pioglitazone, a member of the thiazolidinedione family of drugs known for its antihyperglycemic properties, on lipoprotein (a) [Lp(a)]. Pioglitazone is recognized for enhancing insulin sensitivity and β-cell function, and it also has a positive influence on the overall lipid profile. Recent Findings: Meta-analysis of 7 studies (4 RCTs and three non-RCTs) including 254 patients showed a significant decrease of circulating Lp(a) levels after treatment with pioglitazone (SMD: -0.373, 95% CI: -0.642, -0.104, p = 0.007). The reduction in circulating Lp(a) was robust in the leave-one-out sensitivity analysis. The presented results were obtained following a comprehensive literature search conducted in PubMed, Scopus, Embase, and Web of Science, covering studies from their inception up to March 1, 2025. Summary: Pioglitazone significantly decreases circulating Lp(a) concentrations. This decrease might have a beneficial effect on atherosclerotic cardiovascular disease (ASCVD) in high-risk patients.
KW - Atherosclerosis
KW - Cardiovascular disease
KW - Lipoprotein(a)
KW - Meta-analysis
KW - Pioglitazone
UR - https://www.scopus.com/pages/publications/105017185672
U2 - 10.1007/s11883-025-01346-3
DO - 10.1007/s11883-025-01346-3
M3 - Review article
C2 - 41003906
AN - SCOPUS:105017185672
SN - 1523-3804
VL - 27
JO - Current Atherosclerosis Reports
JF - Current Atherosclerosis Reports
IS - 1
M1 - 94
ER -
